Lead: On March 26, 2026, the International Olympic Committee announced a new policy that will bar transgender athletes from competing in the female category at the Olympic Games, effective at the 2028 Summer Games in Los Angeles. The rule ties eligibility to a one‑time genetic screen for the SRY gene, according to the IOC, which says the measure is intended to protect fairness and safety. IOC President Kirsty Coventry said in a video statement that even the smallest margins can decide victory, and that biological males should not compete in the female category. The move follows controversies at Paris 2024 and a multi‑year IOC review.
Key Takeaways
- The IOC announced on March 26, 2026, that SRY gene screening will determine eligibility for the female category beginning at LA2028.
- Testing is described as a one‑time, mandatory screen for the SRY (Sex‑determining Region Y) gene using a cheek swab or blood sample.
- Exceptions are described as “rare” for conditions such as Complete Androgen Insensitivity Syndrome, but the appeals and access process remains unspecified.
- Scientific critics, including Andrew Sinclair (discoverer of SRY), argue the presence of SRY alone does not reliably predict male‑typical development or performance advantage.
- Advocates warn the policy risks privacy violations, discrimination against intersex people, and extra costs (tests estimated around $250) that could burden athletes and federations.
- Political context includes a February 2025 U.S. executive order restricting trans women in sport, and 27 U.S. states with laws barring trans girls from school teams.
- High‑profile cases influencing debate include weightlifter Laurel Hubbard (Tokyo 2021) and gender‑eligibility scrutiny at Paris 2024 involving boxers including Imane Khelif.
Background
Questions about sex verification in elite sport are long‑running. In the 20th century, women at international competitions faced physical inspections and, later, chromosome tests; the IOC adopted and later abandoned mandatory testing as scientific and ethical concerns mounted. The SRY gene was discovered in 1990 and has been used in some sporting decisions, but its interpretation is contested within the scientific community.
The Paris 2024 Olympics intensified public debate when two female boxers faced scrutiny over eligibility after failing prior world‑championship tests; one was later cleared and the other is pursuing a legal challenge. Laurel Hubbard remains the only openly transgender woman known to have competed in Olympic weightlifting (Tokyo 2021), and no athlete who transitioned after being assigned male at birth is known to have competed in an Olympics since Tokyo.
Political pressures have grown in recent years. In February 2025, U.S. President Donald Trump signed an executive order aimed at banning trans women from women’s sports at all ages and threatened to withhold federal funds; the NCAA moved swiftly to comply. These developments formed part of the wider legal and legislative landscape, including 27 U.S. states that have laws barring trans girls from publicly funded school sports.
Main Event
On March 26, 2026, IOC President Kirsty Coventry announced the policy in a live‑streamed briefing from Lausanne, Switzerland. The IOC said eligibility for the female category will be determined by a one‑time SRY gene screen and that the rule will apply at the Olympics beginning in Los Angeles in 2028. Coventry said the decision followed a multi‑year review and is intended to preserve fairness given how small margins often decide outcomes at the Games.
The IOC statement says a positive SRY result is “highly accurate evidence that an athlete has experienced male sex development,” and that rare medical exceptions may be allowed, including for Complete Androgen Insensitivity Syndrome and some differences in sex development. The committee did not, however, set out a clear, public process for how athletes would access exceptions or appeal decisions.
Scientific and civil‑rights groups immediately raised objections. Critics questioned the test’s diagnostic limits, potential for lab error or contamination, and whether SRY presence equates to any athletic advantage. Intersex advocates also warned the screening could single out athletes whose anatomy or genetics do not fit simple binary definitions, and they expressed concern about privacy and the handling of sensitive genetic data.
Analysis & Implications
The IOC frames the policy as a rules‑based effort to protect a female competitive category, but the practicalities raise multiple challenges. From a scientific perspective, SRY presence alone does not reveal downstream effects such as testis formation, endogenous testosterone production, or androgen receptor function—factors that more directly affect physiology and performance. The scientist who discovered SRY has publicly cautioned against using the gene as a sole determinant of sex development.
Operationally, the testing introduces costs and administrative burdens. Reported estimates put the screening fee at roughly $250 per test; where that cost falls—on athletes, national federations, or organizers—remains unclear. For athletes from low‑resource countries or smaller federations, added costs and the risk of disqualification could reduce participation and deepen inequalities in international sport.
There are also legal and privacy risks. Several European countries, including France and Norway, prohibit genetic testing outside medical or research contexts, which could force athletes to travel for testing or collide with national laws. The storage, access, and governance of genetic results—especially when held by an international body—raise questions about consent, confidentiality, and potential misuse.
Comparison & Data
| Item | Past Practice | IOC 2026 Policy |
|---|---|---|
| Verification method | Physical exams → chromosomal tests → largely dropped (1999) | One‑time SRY gene screening (cheek swab or blood) |
| Exceptions | Case‑by‑case limited | “Rare exceptions” for specific DSDs (e.g., CAIS) |
| Effective date | N/A | 2028 Summer Games (Los Angeles) |
| Estimated test cost | Varied | Approx. $250 reported |
This comparison highlights that the IOC has returned to a form of genetic verification not used widely since the late 20th century, but with a narrower molecular focus. The table is illustrative rather than exhaustive: many scientific, legal and procedural details remain unspecified, which complicates implementation and cross‑jurisdictional compliance.
Reactions & Quotes
“At the Olympic Games, even the smallest margins can be the difference between victory and defeat. So, it is absolutely clear that it would not be fair for biological males to compete in the female category.”
Kirsty Coventry, IOC President (video statement)
Coventry framed the change as protecting competitive integrity and said the policy resulted from the IOC’s internal review. She also emphasized that rules can be challenged and that further details will be released in coming months.
“All it tells you is whether or not the gene is present. It does not tell you how SRY is functioning, whether a testis has formed, whether testosterone is produced and, if so, whether it can be used by the body.”
Andrew Sinclair, geneticist (discoverer of SRY)
Sinclair has publicly opposed using SRY alone as a sex‑determination tool, arguing that presence of the gene is not equivalent to physiological effect or competitive advantage.
“A process like that is going to run up into all the same thorny things … is this going to involve an examination of a girl’s body? … Will it require further biomedical testing?”
Erika Lorshbough, executive director, interACT (intersex youth advocacy)
Intersex advocates highlighted privacy risks and the potential for invasive follow‑up procedures; they also warned of chilling effects that could deter athletes from participation.
Unconfirmed
- It is not yet public which body or laboratory network will administer and certify SRY testing for Olympic eligibility.
- Who will bear the cost of testing—athletes, national federations, or the IOC—has not been specified and may vary by country or sport.
- Details on timelines, appeals procedures, and how “rare exceptions” will be adjudicated remain unpublished and untested in practice.
Bottom Line
The IOC’s decision to use SRY genetic screening to bar transgender athletes from women’s events marks a significant policy shift with scientific, legal and ethical ramifications. While the committee frames the measure as necessary to preserve fairness at the elite level, scientists, advocates and some national laws raise immediate questions about the test’s validity, privacy protections, and cross‑border legality.
Practical implementation—who pays for tests, which labs are authorized, how exceptions are processed, and how appeals are handled—will shape the policy’s real‑world effects. The rule may reduce participation, add costs, and create new legal challenges, while also influencing domestic policy debates and sports governance beyond the Olympic Movement.
As details emerge, stakeholders from national federations to athletes, legal systems and scientific bodies will need clarity on procedures and protections. The next two years before LA2028 are likely to see legal challenges, country‑level friction over testing laws, and further scientific scrutiny of whether SRY screening is an appropriate mechanism for determining competitive categories.